1. N. Howlader, A.M. Noone, M. Krapcho, D. Miller, A. Brest, M. Yu, J. Ruhl, Z, Tatalovich, A. Mariotto, D.R. Lewis, H.S. Chen, E.J. Feuer, K.A. Cronin (eds), SEER Cancer Statistics Review, 1975-2017, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2017/, based on November 2019 SEER data submission, posted to the SEER web site, April 2020.
2. Ovarian cancer population screening and mortality after long-term follow-up in the UK collaborative trial of ovarian cancer screening (UKCTOCS): a randomised controlled trial;Menon;The Lancet.,2021
3. Treatment of recurrent ovarian cancer;Pignata;Ann. Oncol.,2017
4. Rucaparib: an emerging parp inhibitor for treatment of recurrent ovarian cancer;Musella;Cancer Treat. Rev.,2018
5. Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment;Papa;J. Transl. Med.,2016